RESUMO
The introduction of N-substituted pyrazoles in a new series of CCR5 antagonists was shown to substantially increase antiviral activity.
Assuntos
Fármacos Anti-HIV/química , Antagonistas dos Receptores CCR5 , Pirazóis/química , Fármacos Anti-HIV/síntese química , Fármacos Anti-HIV/farmacologia , Humanos , Pirazóis/síntese química , Pirazóis/farmacologia , Receptores CCR5/metabolismo , Relação Estrutura-AtividadeRESUMO
The bicyclic 5-amino-3-azabicyclo[3.3.0]octanes were shown to be effective replacements for the 3-amino-8-azabicyclo[3.2.1]octane found in the CCR5 antagonist maraviroc.
Assuntos
Fármacos Anti-HIV/química , Compostos Azabicíclicos/química , Antagonistas dos Receptores CCR5 , Cicloexanos/química , Inibidores da Fusão de HIV/química , Triazóis/química , Fármacos Anti-HIV/síntese química , Fármacos Anti-HIV/farmacologia , Linhagem Celular Tumoral , Cicloexanos/síntese química , Cicloexanos/farmacologia , Inibidores da Fusão de HIV/síntese química , Inibidores da Fusão de HIV/farmacologia , Humanos , Maraviroc , Modelos Químicos , Receptores CCR5/metabolismo , Triazóis/síntese química , Triazóis/farmacologiaRESUMO
Replacement of a secondary amide with an N-acyl or N-sulfonyl gem-disubstituted azacyle in a series of CCR5 antagonists led to the identification of compounds with excellent in vitro HIV antiviral activity and increased intrinsic membrane permeability.
Assuntos
Amidas/química , Fármacos Anti-HIV/química , Compostos Aza/química , Antagonistas dos Receptores CCR5 , Inibidores da Fusão de HIV/química , Fármacos Anti-HIV/síntese química , Fármacos Anti-HIV/farmacologia , Compostos Aza/síntese química , Compostos Aza/farmacologia , Linhagem Celular Tumoral , Permeabilidade da Membrana Celular/efeitos dos fármacos , Inibidores da Fusão de HIV/síntese química , Inibidores da Fusão de HIV/farmacologia , Humanos , Receptores CCR5/metabolismoRESUMO
The bicyclic 5-amino-3-azabicyclo[3.3.0]octanes were shown to be effective replacements for the conformationally restricted 4-aminopiperidine ring found in several series of CCR5 antagonists.
Assuntos
Antagonistas dos Receptores CCR5 , Avaliação Pré-Clínica de Medicamentos , Piperidinas/química , Modelos MolecularesRESUMO
Starting with a high-throughput screening lead, a novel series of CCR5 antagonists was developed utilizing an information-based approach. Improvement of pharmacokinetic properties for the series was pursued by SAR exploration of the lead template. The synthesis, SAR and biological profiles of the series are described.
Assuntos
Fármacos Anti-HIV/química , Benzamidas/química , Antagonistas dos Receptores CCR5 , Inibidores da Fusão de HIV/química , Pirróis/química , Animais , Fármacos Anti-HIV/síntese química , Fármacos Anti-HIV/farmacocinética , Benzamidas/síntese química , Benzamidas/farmacologia , Inibidores da Fusão de HIV/síntese química , Inibidores da Fusão de HIV/farmacocinética , Humanos , Microssomos Hepáticos/metabolismo , Pirróis/síntese química , Pirróis/farmacocinética , Ratos , Receptores CCR5/metabolismo , Relação Estrutura-AtividadeRESUMO
DNA-encoded libraries (DELs) have generated recent interest due to their ability to provide new small molecule ligands for pharmaceutically important proteins. The chemical diversity of DELs determines their ability to provide potent, novel, and drug-like chemical matter, and DEL chemical diversity is limited by the scope of DNA-compatible chemical reactions. Herein, the one-pot three-component Van Leusen chemistry is applied to DEL synthesis, providing the first reported DNA-compatible method to generate novel highly functionalized imidazoles.
Assuntos
DNA/química , Imidazóis/síntese química , Ciclização , Imidazóis/química , Estrutura Molecular , Bibliotecas de Moléculas PequenasRESUMO
The importance of Discoidin Domain Receptor 1 (DDR1) in renal fibrosis has been shown via gene knockout and use of antisense oligonucleotides; however, these techniques act via a reduction of DDR1 protein, while we prove the therapeutic potential of inhibiting DDR1 phosphorylation with a small molecule. To date, efforts to generate a selective small-molecule to specifically modulate the activity of DDR1 in an in vivo model have been unsuccessful. We performed parallel DNA encoded library screens against DDR1 and DDR2, and discovered a chemical series that is highly selective for DDR1 over DDR2. Structure-guided optimization efforts yielded the potent DDR1 inhibitor 2.45, which possesses excellent kinome selectivity (including 64-fold selectivity over DDR2 in a biochemical assay), a clean in vitro safety profile, and favorable pharmacokinetic and physicochemical properties. As desired, compound 2.45 modulates DDR1 phosphorylation in vitro as well as prevents collagen-induced activation of renal epithelial cells expressing DDR1. Compound 2.45 preserves renal function and reduces tissue damage in Col4a3-/- mice (the preclinical mouse model of Alport syndrome) when employing a therapeutic dosing regime, indicating the real therapeutic value of selectively inhibiting DDR1 phosphorylation in vivo. Our results may have wider significance as Col4a3-/- mice also represent a model for chronic kidney disease, a disease which affects 10% of the global population.
Assuntos
DNA/genética , Receptor com Domínio Discoidina 1/antagonistas & inibidores , Rim/fisiopatologia , Nefrite Hereditária/genética , Animais , Autoantígenos/genética , Autoantígenos/metabolismo , Colágeno Tipo IV/genética , Colágeno Tipo IV/metabolismo , Receptor com Domínio Discoidina 1/metabolismo , Modelos Animais de Doenças , Células Epiteliais/metabolismo , Testes de Função Renal , Camundongos , Camundongos Knockout , Nefrite Hereditária/fisiopatologia , Fosforilação , Proteína 1 de Transformação que Contém Domínio 2 de Homologia de Src/metabolismoRESUMO
To optimize future DNA-encoded library design, we have attempted to quantify the library size at which the signal becomes undetectable. To accomplish this we (i) have calculated that percent yields of individual library members following a screen range from 0.002 to 1%, (ii) extrapolated that â¼1 million copies per library member are required at the outset of a screen, and (iii) from this extrapolation predict that false negative rates will begin to outweigh the benefit of increased diversity at library sizes >108. The above analysis is based upon a large internal data set comprising multiple screens, targets, and libraries; we also augmented our internal data with all currently available literature data. In theory, high false negative rates may be overcome by employing larger amounts of library; however, we argue that using more than currently reported amounts of library (â«10 nmoles) is impractical. The above conclusions may be generally applicable to other DNA encoded library platforms, particularly those platforms that do not allow for library amplification.